Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

✍ Scribed by Miles, D W; de Haas, S L; Dirix, L Y; Romieu, G; Chan, A; Pivot, X; Tomczak, P; Provencher, L; Cortés, J; Delmar, P R; Scherer, S J

• Book ID: 120290067
• Publisher: Nature Publishing Group
• Year: 2013
• Tongue: English
• Weight: 366 KB
• Volume: 108
• Category: Article
• ISSN: 0007-0920
• DOI: 10.1038/bjc.2013.69